Based on these data, it is reasonable to speculate that the FXa inhibitor, RIV, may exert cardioprotective effects on the pathological development of myocardial fibrosis through PAR-2 and TGF-β1 signaling. This evidence concerns the gene TGFB1 and Myocardial fibrosis.